EBMT 2022 | Improving access to CAR-T therapy by reducing turnaround time
Bernd Eschgfaeller, PhD, Novartis Pharma AG, Basel, Switzerland, talks on improving the access to chimeric antigen receptor T-cell (CAR-T) therapies in Europe. Although most countries in Europe have access to CAR-T therapy, it is still necessary to reduce the time between reimbursement approval and the start of CAR-T therapy. Nevertheless, the perspectives for CAR-T therapies are bright, with hundreds of clinical trials evaluating new CAR-Ts products as well as CAR-Ts in new indications. Dr Eschgfaeller highlights Novartis’ T-Charge program, which aims to reduce the CAR-T turnaround time to 7-10 days. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Full time employee of Novartis Pharma AG
